PacBio Shares Drop 16% on Weak Q1 Revenue Growth, Lower Guidance
PacBio’s Q1 revenue rose just 0.1% year over year, missing expectations and prompting a full-year guidance cut. Pacific Biosciences of California (PACB) saw its shares plunge 16% after reporting Q1 results that fell short of revenue expectations. The company posted non-GAA